Background: EDIL3 is an extracellular matrix protein that plays a key role in angiogenesis.
Changes in the pattern of its expression also affect cellular processes and the tumor microenvironment.
Elevated level of EDIL3 is considered an unfavorable prognostic marker of survival.
Objective: The aim of this study was to evaluate the changes in EDIL3 expression in endometrial cancer
at various degrees of its differentiation (G1-G3) and to discuss its potential role as a molecular diagnostic
marker and therapeutic target.
Methods: The study group consisted of 45 patients with endometrial cancer: G1, 17; G2, 15; G3, 13.
The control group (C) included 15 patients without neoplastic changes. The expression of EDIL3 was
assessed using immunohistochemistry. Statistical analysis was performed using the Statistica 12 PL
Results: Analysis of EDIL3 expression showed that the average optical density of the reaction product
in G1 reached 130% of the control, while the values in G2 and G3 were 153% and 158%, respectively.
Regardless of the endometrial cancer grade, an increase in EDIL3 level was observed compared to the
Conclusion: In our study, we demonstrated overexpression of EDIL3 protein in endometrial cancer. Differences
in expression between degrees of tumor differentiation suggest the potential of using changes in
EDIL3 level as a new complementary diagnostic marker and target for anti-angiogenic therapy.